Pasithea Therapeutics (NASDAQ:KTTA) Receives Sell (E) Rating from Weiss Ratings

Weiss Ratings restated their sell (e) rating on shares of Pasithea Therapeutics (NASDAQ:KTTA) in a research note released on Tuesday,Weiss Ratings reports.

Pasithea Therapeutics Stock Performance

Pasithea Therapeutics stock opened at $0.74 on Tuesday. The stock has a fifty day moving average of $0.75 and a two-hundred day moving average of $0.91. The company has a market capitalization of $5.48 million, a price-to-earnings ratio of -0.10 and a beta of 0.27. Pasithea Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $4.59.

Pasithea Therapeutics (NASDAQ:KTTA) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.66) earnings per share for the quarter.

Hedge Funds Weigh In On Pasithea Therapeutics

A hedge fund recently raised its stake in Pasithea Therapeutics stock. AdvisorShares Investments LLC grew its stake in shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA) by 261.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 193,547 shares of the company’s stock after buying an additional 140,000 shares during the period. AdvisorShares Investments LLC owned 2.60% of Pasithea Therapeutics worth $140,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 23.92% of the company’s stock.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.